Evropska unija - slovenščina - EMA (European Medicines Agency)

vbi vaccines b.v. - površinski antigen hepatitisa b - hepatitis b - cepiva - prehevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis b virus in adults. it can be expected that hepatitis d will also be prevented by immunisation with prehevbri as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection. the use of prehevbri should be in accordance with official recommendations.

Evropska unija - slovenščina - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - površinski antigeni virusa influence (hemaglutinin in nevraminidaza) seva a / viet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - cepiva - aktivna imunizacija proti podtipu h5n1 virusa influenca a. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

Evropska unija - slovenščina - EMA (European Medicines Agency)

sanofi pasteur - hepatitis b surface antigen, diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens pertussis toxoid filamentous haemagglutinin, poliovirus (inactivated) type 1 (mahoney) type 2 (mef-1) type 3 (saukett), haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to tetanus protein - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vaccines, bacterial and viral vaccines, combined - hexacima (dtap-ipv-hb-hib) je indicirano za osnovno in obnovitveno cepljenje dojenčkov in malčkov iz šestih tednih starosti proti davici, tetanus, oslovski kašelj, hepatitis b, otroški ohromelosti in invazivnih bolezni, ki povzroča haemophilus influenzae tipa b (hib). uporaba tega cepiva mora biti v skladu z uradnimi priporočili.

Evropska unija - slovenščina - EMA (European Medicines Agency)

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - cepiva - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.

Evropska unija - slovenščina - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - hepatitis b, rekombinantni površinski antigen - hepatitis b; immunization - cepiva - 5 micrograms hbvaxpro is indicated for active immunisation against hepatitis-b-virus infection caused by all known subtypes in individuals from birth through 15 years of age considered at risk of exposure to hepatitis-b virus. posebno ogroženih kategorij, da se immunised določi na podlagi uradnih priporočil. pričakovati je, da se hepatitis d bo prav tako mogoče preprečiti z imunizacijo z hbvaxpro, kot je hepatitis d (zaradi delta agent) ne pride v odsotnosti hepatitis-b, okužbe. 10 micrograms hbvaxpro is indicated for active immunisation against hepatitis-b-virus infection caused by all known subtypes in individuals 16 years of age or more considered at risk of exposure to hepatitis-b virus. posebno ogroženih kategorij, da se immunised določi na podlagi uradnih priporočil. pričakovati je, da se hepatitis d bo prav tako mogoče preprečiti z imunizacijo z hbvaxpro, kot je hepatitis d (zaradi delta agent) ne pride v odsotnosti hepatitis-b, okužbe. 40 micrograms hbvaxpro is indicated for the active immunisation against hepatitis-b-virus infection caused by all known subtypes in predialysis and dialysis adult patients. pričakovati je, da se hepatitis d bo prav tako mogoče preprečiti z imunizacijo z hbvaxpro, kot je hepatitis d (zaradi delta agent) ne pride v odsotnosti hepatitis b okužbe.

Evropska unija - slovenščina - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - cepiva - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Evropska unija - slovenščina - EMA (European Medicines Agency)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - cepiva - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. uporaba tega cepiva mora biti v skladu z uradnimi priporočili.

Evropska unija - slovenščina - EMA (European Medicines Agency)

mcm vaccine b.v. - davica toxoid, tetanus toxoid, bordetella oslovskemu kašlju antigenov: oslovskemu kašlju toxoid, nitastih haemagglutinin, pertactin, fimbriae vrste 2 in 3, hepatitis b surface antigen, proizvedene v kvas celice, poliovirus (inaktivirano): tip 1 (mahoney), tip 2 (mef-1), tip 3 (saukett), ki v chicagu celic/ haemophilus influenzae tipa b polysaccharide (polyribosylribitol fosfat) konjugiran na meningococcal beljakovin. - meningitis, haemophilus; poliomyelitis; tetanus; diphtheria; whooping cough; hepatitis b - cepiva - vaxelis (dtap-hb-ipv-hib) je indicirano za osnovno in obnovitveno cepljenje pri dojenčkih in malčkih od starosti 6 tednov, proti davici, tetanus, oslovski kašelj, hepatitis b, otroški ohromelosti in invazivnih bolezni, ki povzroča haemophilus influenzae tipa b (hib). uporaba zdravila vaxelis mora biti v skladu z uradnimi priporočili.

Evropska unija - slovenščina - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - hepatitis a virus (inactivated), hepatitis b surface antigen - hepatitis b; hepatitis a; immunization - cepiva - zdravilo ambirix se uporablja za osebe, ki niso imune, od enega leta do vključno 15 let, za zaščito pred okužbo s hepatitisom a in hepatitisom b. zaščita proti hepatitis-b, okužbe, morda ne bo mogoče uporabiti, dokler se po drugem odmerku. zato:ambirix je treba uporabiti le, ko je relativno nizko tveganje za hepatitis-b okužbo v času cepljenja seveda;priporočljivo je, da ambirix je treba dajati v okolju, kjer je zaključek dveh odmerek cepljenja seveda lahko prepričani,.

Evropska unija - slovenščina - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - hepatitis a virus (inaktivirano), hepatitis b površinski antigen - hepatitis b; hepatitis a; immunization - cepiva - zdravilo twinrix adult je indicirano za uporabo pri neimunskih odraslih in mladostnikih, starih 16 let ali več, ki jim grozi okužba s hepatitisom a in hepatitisom b.